650 related articles for article (PubMed ID: 25345427)
1. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
[TBL] [Abstract][Full Text] [Related]
2. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Devineni D; Polidori D; Curtin CR; Murphy J; Wang SS; Stieltjes H; Wajs E
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):438-46. PubMed ID: 25907176
[TBL] [Abstract][Full Text] [Related]
4. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
[TBL] [Abstract][Full Text] [Related]
5. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
[TBL] [Abstract][Full Text] [Related]
6. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
[TBL] [Abstract][Full Text] [Related]
7. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.
Devineni D; Manitpisitkul P; Murphy J; Stieltjes H; Ariyawansa J; Di Prospero NA; Rothenberg P
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):279-86. PubMed ID: 27136908
[TBL] [Abstract][Full Text] [Related]
8. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin.
Yan JH; Meyers D; Lee Z; Danis K; Neelakantham S; Majumdar T; Rebello S; Sunkara G; Chen J
J Clin Pharmacol; 2014 Jul; 54(7):800-8. PubMed ID: 24619917
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
11. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates PE; Mesure R
Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
[TBL] [Abstract][Full Text] [Related]
12. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
Smulders RA; Kuipers ME; Krauwinkel WJ
Br J Clin Pharmacol; 2006 Aug; 62(2):210-7. PubMed ID: 16842396
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Chong E; Kalia V; Willsie S; Winkle P
J Nephrol; 2014 Dec; 27(6):659-66. PubMed ID: 24699894
[TBL] [Abstract][Full Text] [Related]
14. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive.
Bush M; Scott R; Watanalumlerd P; Zhi H; Lewis E
Postgrad Med; 2012 Nov; 124(6):55-72. PubMed ID: 23322139
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti CE; O'Leary CM; Hendy CH; Waters DH; Margolis MB
Contraception; 2011 Jan; 83(1):55-61. PubMed ID: 21134504
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello W; Rosenkranz B; Schmid B; Wierich W
Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
[TBL] [Abstract][Full Text] [Related]
17. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Stieltjes H; Wajs E
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):129-38. PubMed ID: 25500487
[TBL] [Abstract][Full Text] [Related]
18. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Kadokura T; Groenendaal D; Heeringa M; Mol R; Verheggen F; Garcia-Hernandez A; Onkels H
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):1-9. PubMed ID: 23754514
[TBL] [Abstract][Full Text] [Related]
19. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
20. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Young A; Anzures-Cabrera J; Derks M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
